Trial Profile
A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Durvalumab in Human Leukocyte Antigen (HLA)-A2+ Subjects Following Standard Treatment of Stage II or III Triple Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs PVX 410 (Primary) ; Durvalumab; Poly ICLC
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- 13 Nov 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2025.
- 13 Nov 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 21 Dec 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.